• Nektar Therapeutics recently hosted an investor call to review 52-week topline results from the 16-week extension of its ongoing Phase 2b REZOLVE-AA trial of investigational rezpegaldesleukin, a regulatory T-cell proliferator for severe-to-very-severe alopecia areata, with detailed materials posted on the company’s website.
• This readout matters because it extends the evidence base for rezpegaldesleukin in a high-need autoimmune hair loss indication, potentially informing next steps alongside its atopic dermatitis program.
• We’ll now explore how the new 52-week REZOLVE-AA data for rezpegaldesleukin could reshape Nektar’s REZPEG-centered investment narrative.

Uncover the next big thing with 26 elite penny stocks that balance risk and reward.

Nektar Therapeutics Investment Narrative Recap

To own Nektar today, you have to believe rezpegaldesleukin can translate its mid‑stage autoimmune data into a viable, de‑risked late‑stage franchise before cash pressures and dilution erode value. The new 52‑week REZOLVE‑AA extension readout is a key check‑in on that thesis, but it does not yet change the fact that the near term catalyst remains Phase 3 initiation and execution in atopic dermatitis, while the biggest risk is continued heavy losses without a clear path to commercialization.

The most closely linked recent announcement is Nektar’s plan to start the ZENITH‑AD Phase 3 program for rezpegaldesleukin in moderate‑to‑severe atopic dermatitis in Q2 2026. Together with the updated REZOLVE‑AA data, this positions REZPEG’s dermatology profile as the central driver of sentiment around Nektar, tying clinical progress in both indications to future funding needs, potential partnerships, and how investors weigh dilution risk against upside from a successful late‑stage program.

Yet while enthusiasm is building, investors should also understand how continued losses and the risk of further dilution could still weigh on Nektar’s story...

Nektar Therapeutics' narrative projects $46.8 million revenue and $9.3 million earnings by 2029. This requires a 5.4% yearly revenue decline and about a $173.4 million earnings increase from -$164.1 million today.

Uncover how Nektar Therapeutics' forecasts yield a $128.12 fair value, a 51% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming revenue could reach about US$128.1 million by 2029, but the new REZOLVE‑AA data may either reinforce or challenge that view, especially if you worry about ongoing R&D losses and the possibility of more equity raises to fund late stage trials.

Explore 3 other fair value estimates on Nektar Therapeutics - why the stock might be worth just $128.12!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Nektar Therapeutics research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.
• Our free Nektar Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Nektar Therapeutics' overall financial health at a glance.

No Opportunity In Nektar Therapeutics?

Our top stock finds are flying under the radar-for now. Get in early:

• Outshine the giants: these 19 early-stage AI stocks could fund your retirement.
• Rare earth metals are the new gold rush. Find out which 31 stocks are leading the charge.
• Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.